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PENJELASAN CIRI-CIRI KLINIKAL DAN MAKMAL, RISIKO-RISIKO 
KOMORBIDITI, PILIHAN RAWATAN DAN PATOFISIOLOGI 
MOLEKULAR PESAKIT-PESAKIT SINDROM ANTIFOSFOLIPID (APS) 
ABSTRAK 
Sindrom antifosfolipid (APS) adalah penyakit autoimun sistemik yang 
disifatkan dengan kehadiran peredaran antibodi antifosfolipid (aPLs) seperti 
antikoagulan lupus (LA), antikardiolipin (aCL) dan anti-β2 glikoprotein I antibodi (β2-
GPI) fosfolipid yang mengikat kepada protein. Walaupun penyakit ini telah wujud 
kira-kira 35 tahun lalu, kriteria diagnostik, faktor-faktor risiko, patogenesis, aspek-
aspek genetic dan strategi rawatan kurang difahami serta belum dibangunkan 
sepenuhnya. Dalam kajian komprehensif ini, ciri-ciri klinikal dan makmal, faktor-
faktor risiko genetik, risiko komorbiditi, patofisiologi molekular dan strategi rawatan 
optimum kepada pesakit-pesakit APS dikaji. Kaedah pengekstrakan dan penulenan 
RNA yang berkualiti dan berintegriti tinggi diperolehi daripada sel mononuklear darah 
periferal manusia (PBMC) yang telah dioptimumkan (kelajuan pengempar: 14000rpm 
+ masa putaran: 75 saat + rawatan DNase + perencat ribolock RNase perencat + 
pembersih RNA) yang boleh digunakan untuk menghantar RNA pesakit APS untuk 
tujuan penjujukan RNA. Dalam usaha mencari pesakit-pesakit APS, dua kajian telah 
dijalankan. Pertama, kes APS primer di kalangan keluarga dari Sarawak Malaysia; 
walaubagaimanapun pesakit-pesakit telah menghidap seronegatif and menerima 
rawatan warfarin dalam tempoh masa yang lama. Kes yang lain yang melibatkan 
subjek APS adalah dari Hospital Universiti Sains Malaysia (HUSM) yang telah 
disiasat secara retrospektif dengan menyiasat strategi klinikal, makmal dan rawatan. 
Kejadian morbiditi kehamilan yang tinggi, dan juga ciri klinikal yang luar biasa seperti 
ketidakfungsian hati dan buah pinggang secara berterusan, menorrhagia and sista ovari 
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telah dikaji. Penggunan warfarin secara berintensi sederhana telah berjaya menghalang 
thrombosis daripada berulang. Tambahan pula, disebabkan pesakit-pesakit HUSM 
tidak berminat untuk menyertai kajian ini secara sukarela, kami tidak dapat 
menghantar sample RNA ke BGI untuk penjujukan RNA. Satu ulasan sistematik 
menggunakan analisis bioinformatik telah dijalankan untuk mengenalpasti faktor-
faktor risiko genetik kepada pesakit APS trombotik,  dimana 16 gene dikaitkan dengan 
kesan thrombosis yang kebanyakkan mempengaruhi laluan pembekuan darah dan 
sistem immun yang dikaitkan dengan APS. Secara keseluruhannya, tiga ulasan 
sistematik dan metaanalisis telah dijalankan bagi menentukan pengaruh aPLs pada 
pesakit-pesakit migrain, epilepsi dan dementia tanpa penyakit autoimun dan 
dibandingkan dengan individual kawalan, di mana aPLs dikaitkan dengan komorbid 
yang berkemungkinan bermanifestasi. Oleh itu, ciri-ciri neurologi telah dapat 
dikenalpasti pada peringkat awal klinikal manifastasi sebelum berkembang 
sepenuhnya kepada APS.  Satu ulasan sistematik Cochrane telah dibangunkan untuk 
meneroka strategi rawatan yang optimum untuk subjek-subjek APS trombotik dimana 
pengambilan warfarin secara intensity sederhana adalah lebih baik daripada 
pengambilan warfarin yang berintensiti tinggi. Keseluruhannya, kajian komprehensif 
ini meneroka ciri-ciri klinikal dan makmal, faktor-faktor risiko genetik, risiko 
komorbiditi, patofisiologi molekular dan strategi rawatan optimum untuk pesakit-
pesakit APS telah berjaya dibangunkan. 
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ELUCIDATION OF CLINICAL AND LABORATORY FEATURES, 
COMORBIDITY RISKS, TREATMENT OPTIONS AND MOLECULAR 
PATHOPHYSIOLOGY OF ANTIPHOSPHOLIPID SYNDROME (APS) 
PATIENTS 
ABSTRACT 
Antiphospholipid syndrome (APS) is a systemic autoimmune disease 
characterised by the presence of circulating antiphospholipid antibodies (aPLs) such 
as lupus anticoagulant (LA), anticardiolipin (aCL) and anti-β2-glycoprotein I (β2-GPI) 
antibodies to phospholipid binding proteins. Although the disease has been in 
existence for approximately 35 years, the diagnostic criteria, risk factors, pathogenesis, 
genetic aspects, treatment strategies are poorly understood and have yet to be fully 
developed. In this study, the clinical and laboratory features, genetic risk factors, 
comorbidity risks, molecular pathophysiology and optimal treatment strategy of APS 
patients are explored. Human peripheral blood mononuclear cell (PBMC)-derived 
high-quality and integrity RNA extraction and purification method was optimised 
(centrifugal speed: 14000 rpm + spin time: 75 seconds + DNase treatment + Ribolock 
RNase inhibitor + RNA clean-up) which could be used to send APS patients’ RNA for 
RNA-Seq. In quest of APS patients, two studies were conducted. Firstly, on a familial 
primary APS cases from Sarawak, Malaysia, patients however became seronegative 
following long warfarin therapy. Another one with APS subjects from Hospital 
Universiti Sains Malaysia (HUSM) were retrospectively investigated by exploring the 
clinical, laboratory and treatment strategies. High occurrence of pregnancy morbidity, 
as well as some unusual clinical features such as persistent dysfunction of liver and 
kidneys; menorrhagia and ovarian cyst were observed. The use of medium-intensity 
warfarin was successful in preventing thrombosis recurrence. Additionally, since the 
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HUSM patients were unwilling to participate in this study, we were unable to send the 
RNA samples for RNA-Seq to BGI. A systematic review with bioinformatic analyses 
was conducted to identify the genetic risk factors in thrombotic APS subjects where 
16 genes were significantly associated with thrombosis affecting mostly the blood 
coagulation pathway and the immune system related to APS. Overall, three systematic 
reviews and meta-analyses were conducted to determine the influence of aPLs in 
patients with migraine, epilepsy and dementia without autoimmune disease as 
compared to controls, where aPLs were significantly comorbid with the said 
manifestations. Therefore, the neurologic features were early clinical manifestations 
before the development of full-blown APS. A single Cochrane systematic review was 
developed to explore the optimum treatment strategy for thrombotic APS subjects, 
where, moderate-intensity warfarin was superior than high-intensity warfarin. Overall, 
a comprehensive study exploring the clinical and laboratory features, genetic risk 
factors, comorbidity risks, molecular pathophysiology and optimal treatment strategy 
of APS patients was successfully established. 
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CHAPTER 1 
INTRODUCTION 
1.0 Introduction 
1.1 Antiphospholipid syndrome 
Antiphospholipid syndrome (APS) or Hughes syndrome is a systemic autoimmune 
disease that was first described in 1983 (Hughes). Clinically, it is characterised by 
vascular thrombosis (venous and/or arterial) and/or pregnancy complications besides 
the presence of serum antiphospholipid antibodies (aPLs) such as lupus anticoagulant 
(LA), anticardiolipin (aCL) antibodies and anti-β2-glycoprotein I (β2-GPI) antibodies. 
According to the latest classification criteria (Sydney criteria, Table 1.1), patients can 
only be confirmed as having APS when at least one laboratory marker and a clinical 
feature are present (Miyakis et al., 2006). The major difference between the updated 
Sydney criteria and the first criteria (Sapporo) is the introduction of anti-β2-GPI and 
the addition of the cut-off values of LA, aCL and anti-β2-GPI in laboratory diagnosis 
(Wilson et al., 1999). 
 
1.2 Types of APS 
Broadly, there are three types of APS. APS is considered as primary when the patient 
has core clinical and laboratory features of definitive APS without the existence of 
another autoimmune disease (Asherson et al., 1989). APS is secondary when at least 
one autoimmune disorder co-exists with the disease besides the core clinical and 
laboratory features of APS. In secondary APS, systemic lupus erythematosus (SLE) is 
the mostly observed coexisting autoimmune disease (Alarcón-Segovia et al., 1989) 
while catastrophic APS is the most aggressive form of APS. Besides the clinical and 
laboratory features of APS, it is characterised by thrombi development in the small 
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blood vessels of multiple organs that result in multiple organ failure. Therefore, it is 
considered as the most common reason for the high mortality rate of APS (Cervera et 
al., 2009). 
 
Table 1.1: Sydney classification criteria of APS 
Clinical criteria 
• Vascular thrombosis 
- ≥1 arterial, venous or small vessel thromboses in any tissue or organ 
(excluding superficial thrombosis), as confirmed by appropriate imaging or 
histopathology. 
• Pregnancy morbidity 
- ≥1 unexplained deaths of a morphologically normal foetus at or beyond the 
10th week of gestation. 
- ≥1 premature births or a morphologically normal neonate before the 34th 
week of gestation owing to eclampsia, severe pre-eclampsia or placental 
insufficiency. 
- ≥3 unexplained consecutive spontaneous abortions before the 10th week of 
gestation, with hormonal, chromosomal or maternal anatomical causes 
excluded. 
Laboratory criteria 
- LA present in plasma, detected according to the guidelines of the 
International Society on Thrombosis and Haemostasis. 
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- IgG and/or IgM isotype aCL present in medium to high titre [i.e. >40 IgG 
phospholipid (GPL) or IgM phospholipid (MPL) units] as measured by 
standard enzyme-linked immunosorbent assay (ELISA). 
- IgG and/or IgM isotype anti-β2-GP1 antibody in serum or plasma, present 
in medium/high titre (i.e. >99th percentile). 
Any of the above three must be present on two or more occasions for at least 12 
weeks apart and <5 years. 
To fit the classification, one feature from each set of the clinical and laboratory criteria is required. 
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1.3 Epidemiology 
The incidence of APS is approximately five new cases per 100,000 persons per year 
with an estimated prevalence of approximately 40-50 patients per 100,000, and 
females are 3.5 times more likely to be affected than males (Cervera et al., 2002). The 
total mortality rate was estimated as 9.3%, although it has been reported to be as high 
as 55.6% in catastrophic APS in which severe thrombosis is the most frequent cause 
of deaths (Cervera et al., 2015). Though aPLs is observed in APS patients; in the 
general population, the prevalence of aPLs was estimated as 1-5% (Biggioggero and 
Meroni, 2010). 
 
1.4 Major clinical features of APS  
1.4.1 Thrombosis 
Among the acquired thrombophilic conditions, APS is the most frequently observed 
in young adults and is associated with both arterial and venous thrombosis (Nalli et 
al., 2014). According to Cervera et al., (2015), since APS affects at least 1% of the 
general population, aPL-induced vascular events exert a robust clinical impact and 
burden worldwide. According to the recent 10-year multicentre prospective study on 
1000 APS patients (53.1% primary APS and 36.2% secondary APS), the most 
frequently reported causes of death were severe thrombosis (36.5%) and thrombotic 
events [stroke, transient ischemic attack (TIA), deep vein thrombosis (DVT), 
pulmonary embolism (PE), myocardial infarction (MI) and superficial 
thrombophlebitis] occurring in 21.4% of the patients (Cervera et al., 2015). In APS 
patients, thrombosis (both venous and arterial) is the most common clinical 
manifestation and contributes to the high mortality rate (Santamaria et al., 2005). 
Approximately 55% of APS patients suffer from venous thromboembolism (VTE) 
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including DVT and PE (Hanly, 2003), while cerebrovascular accidents and TIAs are 
the commonest (50%) arterial thrombotic manifestations (Nalli et al., 2014). 
 
In the general population, it has been estimated that aPLs are present in patients with 
stroke (13.5%), MI (11%) and DVT (9.5%) (Andreoli et al., 2013). In fact, almost 20% 
of the patients (age <50 years) with stroke or VTE are APS patients (Roldan et al., 
2009; Ruiz-Irastorza et al., 2011). Despite treatment with antiplatelet and/or 
anticoagulant agents, recurrent thrombosis in APS is a common phenomenon with a 
high occurrence rate (approximately 10%) (Ruiz-Irastorza et al., 2011; Cervera et al., 
2015), possibly because of the lack of appropriate specific targeted regimens against 
the thrombotic pathogenesis of APS. In fact, in a primary APS cohort of Mexican 
ethnics, triple positivity for aPLs was the major independent risk factor for recurrent 
thrombosis (Hernandez-Molina et al., 2013).  
 
In APS patients, thrombi can appear in any tissues and/or organs as confirmed by 
imaging, ultrasound or histopathology studies, except in the case of superficial venous 
thrombosis (Miyakis et al., 2006). Several key factors associated with cell activation 
(Atsumi et al., 1998b; Forastiero et al., 1998; Joseph et al., 2001), coagulation pathway 
(Adams et al., 2004; Giannakopoulos et al., 2012; Dharma et al., 2015), fibrinolytic 
pathway (Takeuchi et al., 2002; Bu et al., 2009), immune system (Hattori et al., 2000; 
Simonin et al., 2015) and genetic factors (Galli et al., 2000; Caliz et al., 2001; Karassa 
et al., 2003) are affected by the interference of aPLs which further contribute to the 
development of thrombotic manifestations in APS. 
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1.4.2 Pregnancy complications 
According to the APS Alliance for Clinical Trials and International Networking (APS 
ACTION) group, aPLs were present in 6% of patients experiencing pregnancy 
morbidity (Andreoli et al., 2013). In a multicentre prospective cohort study, Cervera 
et al. (2002) observed early miscarriages in 35.4% of cases, foetal death in 16.9%, 
premature birth in 10.6%, PE in 9.5%, eclampsia in 4.4% and abruption placentae in 
2% of pregnant APS women (n=590) with 1580 pregnancies. According to the 
European Registry on Obstetric APS, recurrent miscarriage was the most frequently 
observed (approximately 54%) obstetrical complication in women with APS (Alijotas-
Reig et al., 2015). In APS, foetal death is observed due to the possible consequences 
of placental dysfunction which is firmly associated with the presence of aPLs (Silver 
et al., 1993; Abou-Nassar et al., 2011). From the analysis of Stillbirth Collaborative 
Research Network enrolling 512 stillbirths (2006-2008), aPLs were positive in 11.1% 
of the women [95% confidence interval (CI) 8.4-14.4] (Page et al., 2017). 
 
1.5 Non-criteria clinical features of APS 
Besides the definitive clinical criteria of APS, some other clinical manifestations are 
rather frequently observed in APS patients. Since these manifestations have not yet 
been recognised to be included in the criteria clinical features of APS, they are often 
known as non-criteria clinical features and are often observed to comorbid with APS. 
Among the non-criteria features; besides thrombocytopenia; different neurological 
(i.e., migraine, epilepsy and dementia), cardiac, pulmonary, dermatological and renal 
manifestations are frequently observed to comorbid in patients with APS (Table 1.2). 
Nevertheless, the comorbidity risks of these non-criteria features in APS still needs to 
be investigated. 
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Table 1.2: Non-criteria manifestations of APS 
Non-criteria manifestations References 
• Thrombocytopenia (Krause et al., 2005; Cervera 
et al., 2015) 
• Neurological 
- Headache and migraine 
(Cervera et al., 2009; Zhu et 
al., 2014; Abreu et al., 2015) 
- Epilepsy 
(Shoenfeld et al., 2004; 
Stojanovich et al., 2013) 
- Dementia 
(Mosek et al., 2000; Chapman 
et al., 2002) 
- Multiple sclerosis 
(Stosic et al., 2010; 
Koudriavtseva et al., 2014) 
- Psychosis 
(Cardinal et al., 2009; Paz-
Silva et al., 2014) 
- Chorea and other movement disorders 
(Avcin et al., 2008; da Silva 
and de Carvalho, 2014) 
- Cognitive Impairment 
(Jacobson et al., 1999; 
Tektonidou et al., 2006) 
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- Bipolar disorder 
(Raza et al., 2008; Avari and 
Young, 2012) 
- Transverse myelitis 
(D'Cruz et al., 2004; 
Rodrigues and de Carvalho, 
2011) 
• Cardiac 
- Myocardial infarction (Cervera et al., 2015) 
- Cardiac valve abnormalities (Cervera et al., 2011) 
• Pulmonary 
- Pulmonary emboli and infarction (Cervera et al., 2015) 
- Pulmonary hypertension and intra-
alveolar haemorrhage 
(Stojanovich et al., 2012) 
• Dermatological 
- Livedo reticularis (Toubi and Shoenfeld, 2007) 
• Renal 
- Renal insufficiency, acute renal failure 
and hypertension 
(Tektonidou, 2014) 
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1.6 Molecular pathogenesis 
1.6.1 Thrombosis 
Although the complete thrombotic pathophysiology of APS is still unclear, generally, 
the formation of thrombi in APS is mediated by aPL-induced dysregulation of cell 
activation, coagulation, the fibrinolytic pathway, the immune system, genetics and 
some other factors (Negrini et al., 2017). Activation of platelet markers, such as CD63, 
procaspase activating compound-1 (Joseph et al., 2001), CD62 (Fanelli et al., 1997), 
and CD62P (Jy et al., 2007), the formation of a thrombogenic complex between 
homotetrameric platelet factor 4 (PF4) and two dimerised molecules of β2-GPI 
(Vlachoyiannopoulos and Routsias, 2010), activation, elevation of the von Willebrand 
factor (vWF) levels (Lindsey et al., 1993; Cugno et al., 2010), dysfunction of 
ADAMTS13 (a protease enzyme) (Amoura et al., 2004; Crawley et al., 2011), 
dysregulation of prostaglandins [prostacyclin (PGI2), thromboxane A2 (TXA2)] 
(Carreras and Vermylen, 1982; Årfors et al., 1990; Lindsey et al., 1993), annexin A2 
(Ao et al., 2011) and toll-like receptors (TLRs) (Benhamou et al., 2014) are involved 
in platelet activation, adhesion and aggregation, leading to the generation of thrombi 
in APS patients. In addition to impaired fibrinolysis (Atsumi et al., 1998a) in the 
coagulation pathway, the involvement of tissue factors (TFs) (López-Pedrera et al., 
2006), annexin A5 (Rand et al., 2008), proteins C and S (Keeling et al., 1993; Erkan 
et al., 2002), factor XI (Giannakopoulos et al., 2012), tissue factor pathway inhibitor 
(TFPI) (Adams et al., 2004) was also observed in patients with thrombotic APS. The 
activation of the complement system (Pierangeli et al., 2005; Breen et al., 2012), the 
involvement of B and T cells (Conti et al., 2014; Simonin et al., 2015) and tumour 
necrosis factor alpha (TNF-α) (Swadzba et al., 2011; Bećarević et al., 2012) were 
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reported to be the major immune-mediated phenomena contributing to thrombosis in 
APS patients. 
 
1.6.2 Pregnancy complications 
The pathogenesis of aPL-associated recurrent early pregnancy loss (first-trimester) is 
different from that of late pregnancy loss (Derksen and de Groot, 2008). During aPLs-
derived first-trimester pregnancy loss, aPLs have direct inhibitory effects on 
proliferation of trophoblast cells (Chamley et al., 1998; Di Simone et al., 2000). The 
late pregnancy complications of APS such as pre-eclampsia, intrauterine growth 
restriction and stillbirths are the consequence of placental dysfunction by failure of 
extravillous trophoblasts to adequately remodel the spiral arteries, reduced maternal 
blood flow to the placenta resulting hypoxic injury, inadequate supply of nutrients to 
the foetus and high-velocity and high-pressure blood flow that can damage the placenta 
(Burton et al., 2009). aPLs play roles in reducing proliferation and invasion of 
extravillous trophoblasts and triggering inflammation at the maternal-foetal interface, 
which together drive impaired placentation (Abrahams, 2009; Mulla et al., 2009; 
Mulla et al., 2010). β2‑GPI is constitutively expressed on the cell surface of placental 
trophoblasts as well as on maternal decidual endothelial cells (De Groot et al., 2012). 
Interestingly, anti-β2-GPI antibodies can bind with human trophoblasts and the 
endothelium via the domain 5 phospholipid binding site of β2-GPI (Di Simone et al., 
2005). Both in vitro and in vivo studies have reported that aPLs can inhibit spontaneous 
trophoblast migration, increase trophoblast antiangiogenic soluble endoglin secretion 
and disrupt trophoblast-endothelial interactions via low-density lipoprotein receptor-
related protein 8 (LRP8) (Mulla et al., 2009; Mulla et al., 2010; Carroll et al., 2011; 
Alvarez et al., 2015; Ulrich et al., 2016). Injection of immunoglobulin G (IgG) 
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antibodies from an APS patient to pregnant mice resulted in foetal resorption and 
growth restriction (Holers et al., 2002). aPLs is usually localised to the placenta and is 
generated in developing inflammatory responses via different components such as 
complement activation and recruitment and stimulation of neutrophils which result in 
placental insufficiency, foetal loss and growth restriction in APS (Girardi et al., 2003). 
 
1.7 Genetics of APS 
The presence of aPLs was reported in family members even before the development 
of autoimmune diseases. Additionally, higher incidence of aPLs has been reported 
among first degree relatives of primary APS (Exner et al., 1980; Mackworth-Young 
et al., 1987; Goldberg et al., 1995). Both family and non-family studies were reported 
to be linked with major histocompatibility complex (MHC) genes (Willis et al., 2012; 
Sebastiani et al., 2016) in addition to thrombotic genetic markers (Namjou, 2003; 
Castro‐Marrero et al., 2009). Taken together, these scenarios indicate the strong 
possibility of genetic predisposition in APS.  
 
1.8 Management 
1.8.1 Thrombosis 
1.8.1(a) Primary thromboprophylaxis 
Primary thromboprophylaxes are regimens used to prevent thrombosis in those 
without history of previous clots. Asymptotic APS subjects with very high antibody 
titres, triple positive subjects (LA, aCL and anti-β2-GPI antibodies) along with the 
presence of cardiovascular risk factors can be considered for treatment with low-dose 
aspirin or hydroxychloroquine as primary thromboprophylactic agents (Ruiz-Irastorza 
et al., 2011). According to a meta-analysis of observational studies, low-dose aspirin 
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efficiently reduced 50% risk of primary thrombosis development in patients with APS 
(Arnaud et al., 2014), albeit with an increased risk of bleeding (Baigent et al., 2009). 
As an alternative to low-dose aspirin, hydroxychloroquine is successfully applied in 
clinical setting on the basis of findings from in vitro experiments (Wallace et al., 
2012). 
 
1.8.1(b) Secondary thromboprophylaxis 
Secondary thromboprophylaxes are regimens which are used to prevent recurrent 
thrombosis following the first thrombotic event. Selecting an optimum secondary 
thromboprophylaxis has been one of the major challenges in managing thrombotic 
APS patients. Only a few randomised controlled trials (RCTs) have attempted to 
determine the best secondary thromboprophylaxis such as anticoagulants (i.e., 
warfarin) or antiplatelet agents (i.e., aspirin) in preventing recurrence of thrombosis in 
APS (Crowther et al., 2003; Finazzi et al., 2005; Cuadrado et al., 2014; Cohen et al., 
2016), albeit with dissimilar findings. Two systematic reviews (including prospective, 
retrospective studies and RCTs) published in 2006 (Lim et al.) and 2007 (Ruiz‐
Irastorza et al.) have tried to explore the best secondary prophylaxis for thrombotic 
APS with the conclusion of moderate intensity warfarin [international normalised ratio 
(INR): 2-3] to be recommended for recurrent thrombotic APS patients. Recently, non-
vitamin K antagonist oral anticoagulants (NOAC) have been utilised in the 
management of secondary thrombosis in APS (Son et al., 2015) and some RCTs on 
NOACs are also currently ongoing (i.e., NCT02926170, NCT02157272 and 
NCT02295475). 
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1.8.2 Pregnancy complications 
To prevent pregnancy complications in individuals with obstetrical APS, low-dose 
aspirin, intermediate-dose of low molecular weight heparin (LMWH) or 
unfractionated heparin have been reported to be efficient (Bouvier et al., 2013; 
Andreoli et al., 2016). Pregnant APS women with primary thrombotic history require 
intermediate or full-dose anticoagulation (usually LMWH) throughout their 
pregnancies to prevent further thrombotic events (Rey et al., 2009). Based on a 
Cochrane systematic review, 54% of the pregnancy loss could be reduced when 
treating obstetric APS subjects with unfractionated heparin in combination with low-
dose aspirin (Empson et al., 2005). 
 
Although the disease has been known for more than 30 years, the diagnostic criteria, 
risk factors, molecular pathogenesis, genetic aspects and treatment strategies are 
poorly understood and yet to be fully developed. In Malaysia, to date, there are only a 
few studies on APS (Ong et al., 2002; Wan Ali et al., 2011; Hong-Kee et al., 2014), 
however, none has retrospectively evaluated the clinical, laboratory characteristics and 
management strategies of APS patients. Additionally, there is a substantial absence of 
information on risk factors, pathophysiology, genetics and optimal treatment strategies 
for APS patients worldwide. 
 
Therefore, the current study will embark on a widespread exploration of APS towards 
elucidating the clinical and laboratory features of Malaysian APS patients, explore the 
genetic aspects, identify the potential risk factors, molecular pathogenesis, current and 
optimal treatment strategies for better management of APS patients globally. 
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1.9 Objectives 
1.9.1 General objective 
To explore the clinical and laboratory features, genetic risk factors, comorbidity risks, 
molecular pathophysiology and optimal treatment strategy for APS patients. 
 
1.9.2 Specific objectives 
1. To establish an optimised protocol for extracting high-quality and integrity 
RNA from human peripheral blood mononuclear cells (PBMCs) and 
additionally perform Ribonucleic acid (RNA)-Sequencing (RNA-Seq) of APS 
patients from Hospital Universiti Sains Malaysia (HUSM). 
2. To retrospectively examine the criteria and non-criteria clinical and laboratory 
features, as well as treatment strategies of Malaysian APS patients. 
3. To explore the genetic risk factors in thrombotic APS by evolving a systematic 
review with bioinformatic analysis (i.e., functional enrichment, molecular 
interaction, pathway and gene expression). 
4. To elucidate the comorbidity risks of non-criteria manifestations (i.e., 
migraine, epilepsy and dementia) associated with aPLs by developing three 
systematic reviews and meta-analyses. 
5. To identify the optimal treatment strategy in managing thrombotic APS 
patients by developing a Cochrane systematic review and meta-analysis. 
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Figure 1.1: Theoretical Framework of the study 
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CHAPTER 2 
OPTIMISATION OF HIGH-QUALITY RNA 
2.0 Optimisation of high-quality RNA extraction 
2.1 Introduction 
RNA-Seq is a high-throughput next-generation sequencing (NGS) technology which 
is highly efficient to differentially analyse gene sequencing and expression profile of 
both healthy and diseased subjects. The data generated from RNA-Seq offers 
knowledge on pathogenic mechanisms and signalling pathways associated with a 
disease as compared to healthy controls (Ozsolak and Milos, 2011; Tarazona et al., 
2011). Nevertheless, for generating a reliable data from RNA-Seq, it is mandatory to 
have high-quality RNA representing with 1) high purity and 2) high integrity. RNA 
purity is evaluated by determining absorbance260/280 (A260/280) and A260/230 ratios, which 
should ideally be ≥1.8 for high-quality RNA samples. RNA integrity is assessed by 
RNA integrity number (RIN) ranging between 1 and 10, where 1 indicates highly 
degraded RNA samples while 10 indicates highly integrated RNA samples (Schroeder 
et al., 2006). RNA samples with a RIN value of ≥7 is normally considered as integrated 
RNA which is usually appropriate for unbiased RNA-Seq (Madabusi et al., 2006; 
Kiewe et al., 2009). RNA required for RNA-Seq should be free from contamination 
of deoxyribonucleic acid (DNA), nucleases and other proteins, salts, polysaccharides 
and organic compounds. Nevertheless, high-quality RNA is a challenge to obtain 
because RNA is an unstable molecule susceptible to be degraded by endogenous 
RNases which is ubiquitous in the environment (Becker et al., 2010). 
 
PBMCs are peripheral blood cells [approximately 35% of the white blood cells 
(WBCs)] having a spherical nucleus consisting of lymphocytes [T-cells (70%), B-cells 
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(15%), natural killer (NK) cells (10%)] and monocytes (5%) (Autissier et al., 2010; 
Murphy et al., 2016). PBMCs are considered as ideal cell types to extract RNA from, 
since the cells interact with all organs and tissues in the body and consequently present 
gene expression profiles that can reflect the pathophysiological status, behaviours, 
growth stage and lifestyle of subjects (Mohr and Liew, 2007; Peters et al., 2015). 
 
The objective of this study was to establish an optimised protocol for extracting high-
quality RNA from human PBMCs so that high-quality RNA (A260/280 and A260/230 ratios 
≥1.8; RIN ≥7; total RNA ≥1 µg and concentration ≥65 ng/μl) of APS patients 
(following selection and confirmation) can be sent to Beijing Genomics Institute 
(BGI), Hong Kong for RNA-Seq. 
 
2.2 Materials and methods 
2.2.1 RNA extraction from cell lines and lymphocytes 
Before starting with human PBMCs drawn from peripheral blood, first, cultured 
lymphoma cell lines (RL-60, RL-75, HT-60 and HT-75) were used to run the un-
optimised protocol. Later, from a volunteer, 20 ml of peripheral blood was collected 
in K2EDTA tubes (BD Vacutainer, New Jersey, United States). Then, the blood 
sample was immediately transferred into a 50 ml leucosep tube (Greiner Bio-One, 
Kremsmunster, Austria) with porous barrier containing Ficoll-Paque via 5 ml sterile 
transfer pipette. After that the tube containing 20 ml blood was centrifuged (5810R, 
Eppendorf, Hamburg, Germany) for 15 min at 2000 revolutions per min (rpm) 
(switching brakes off) at room temperature. After centrifugation, from the three-
layered sequence, the thick whitish buffy coat was transferred by a Pasteur pipette 
(Sigma-Aldrich, Missouri, United States) to a 50 ml polypropylene tube (BD 
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Biosciences, California United States). Then, the cell fraction was mixed with 25 ml 
of 1x phosphate buffered saline (PBS) (Sigma-Aldrich, Missouri, United States) 
followed by a 10-min centrifugation (5810, Eppendorf, Hamburg, Germany) at 1100 
rpm (brake ± 5). The supernatant was discarded and another 2 ml of 1x PBS was re-
suspended. From there, 10 µL cell suspensions was mixed with 10 µL trypan blue and 
viable cells were counted by a haemocytometer using a microscope (IMT-2, Olympus, 
Tokyo, Japan). 
 
2.2.2 RNA extraction and purification: Protocol A 
RNA extraction and purification were conducted following the protocol of GeneJET 
RNA purification kit (Thermo Scientific, Massachusetts, United States) with slight 
modifications. Before starting the experiments, RNase Zap® was sprayed and wiped 
on microcentrifuge tubes, glassware, plastic surfaces, countertops, pipettes and inside 
the hood to eliminate RNase contamination. Not more than 10 million cell pellets were 
taken into a 2.0 ml eppendorf tube and washed with 1.5 ml of 1x PBS to remove 
residual growth medium. Following 2000 rpm centrifugation (MiniSpin, Eppendorf, 
Hamburg, Germany), the supernatant was removed. Lysis buffer (600 μl) 
supplemented with β-mercaptoethanol (12 μl) was added with the pellet and vortexed 
at 1400 rpm for 10 seconds to mix thoroughly. As cell debris were observed, the 
sample was then centrifuged at 14000 rpm (MiniSpin, Eppendorf, Hamburg, 
Germany) for 5 min followed by the transfer of the supernatant into an RNase-free 
microcentrifuge tube. Subsequently, 360 μl of 100% ethanol was added into the sample 
and mixed by pipetting (15-20 times). Then, 700 μl of lysate was transferred into a 
GeneJET RNA purification column (inserted in a collection tube) and centrifuged for 
75 seconds at 14000 rpm (MiniSpin, Eppendorf, Hamburg, Germany). The flow-
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through was discarded and the step was repeated so that all of the lysate can be 
transferred into the column. Then, the collection tube was discarded with flow-through 
and was replaced with a new collection tube. Then, the column was washed 
subsequently with 700 μl wash buffer 1 and 600 μl wash buffer 2 and centrifuged at 
both 13000 and 14000 rpm for 60, 75 and 90 seconds. Again, the column was washed 
with 250 μl of wash buffer 2 followed by another 2-min centrifugation at both 13000 
and 14000 rpm. After this, as residual solution was seen in the purification column, 
again the column was centrifuged for 1 min at 14500 rpm. Then, the collection tube 
containing the flow-through was discarded and replaced with a new 1.5 ml RNase-free 
microcentrifuge tube. For eluting RNA, 50 μl of nuclease free water was placed at the 
middle of the column membrane and centrifuged for 1 min at both 13000 and 14000 
rpm. The quality of the extracted RNA was estimated (from 2 μl RNA sample) by 
using the Epoch Microplate Spectrophotometer (BioTek, Vermont, United States). 
Nuclease free water (2 μl) was used as the blank sample. The protocol was the 
modified version of the manufacturer’s recommended protocol (Ni et al., 2015; Song 
et al., 2016). 
 
2.2.3 Genomic DNA removal and addition of RiboLock: Protocol B, C and D 
RapidOut DNA removal kit (Life Technologies, California, United States) was used 
for removing genomic DNA from the sample. For 1 μg of RNA, 1 μl 10x reaction 
buffer with magnesium chloride (MgCl2) and 1 μl DNase I (RNase-free) was used. To 
scale up the solution to 10 μl, diethylpyrocarbonate (DEPC)-treated water was used in 
this step (Protocol B). Additionally, RiboLock RNase inhibitor (Life Technologies, 
California, United States) was mixed at 1 U/μl. Then, the mixture was incubated in a 
water bath for 30 min at 37°C (Protocol C). After the incubation, the RNA sample was 
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re-purified by following the RNA clean-up protocol by using a GeneJET RNA 
purification kit (Protocol D). Here, RNA was taken and the volume was adjusted to 
100 μl by adding nuclease free water followed by adding 300 μl lysis buffer without 
β-mercaptoethanol and mixed thoroughly by pipetting. Then, 180 μl ethanol (100%) 
was added and mixed and the mixture was transferred in the GeneJET RNA 
purification column inserted in a collection tube and centrifuged for 1 min at 14000 
rpm (MiniSpin, Eppendorf, Hamburg, Germany). The flow-through was discarded and 
the step was repeated so that all of the lysate can be transferred into the column. Then, 
the collection tube was discarded with flow-through and was replaced with a new 2 ml 
collection tube. Subsequently, the column was washed with 700 μl wash buffer 1 and 
600 μl wash buffer 2 and centrifuged at both 13000 and 14000 rpm for 60, 75 and 90 
seconds. Again, the column was washed with 250 μl of wash buffer 2 followed by 
another 2-min centrifugation at both 13000 and 14000 rpm. Then, the collection tube 
containing the flow-through was discarded and replaced with a new 1.5 ml RNase-free 
microcentrifuge tube. Then, the collection tube containing the flow-through was 
discarded and replaced with a new 1.5 ml RNase-free microcentrifuge tube. The 
quality of the purified intact RNA (without genomic DNA and RNase) was estimated 
(from 2 μl RNA sample) by using the Epoch Microplate Spectrophotometer (BioTek, 
Vermont, United States). Nuclease free water (2 μl) was used as blank. The protocol 
was the modified version of the manufacturer’s recommended protocol (Rocha et al., 
2015; Boguslawska et al., 2016) 
 
2.2.4 RNA integrity number (RIN) check 
RIN of the purified RNA was checked by using a 2200 TapeStation (Agilent, 
California, United States). The R6K ScreenTape (Agilent, California, United States) 
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was used for the quality assessment of total RNA. R6K sample buffer (4 μl) was mixed 
with 1 μl RNA sample followed by heating the samples at 72°C (Thermal cycler, Bio-
Rad Laboratories, California United States) for 3 min. Immediately after heating, the 
sample was placed on ice for 2 min. Then, the sample was loaded in the ScreenTape 
and analysed the RIN by using the Agilent 2200 TapeStation software (version 
A.01.04). 
 
2.3 Results 
In case of the quality of RNA extracted from cell lines, both A260/280 and A260/230 ratios 
were >1.8 for all the four cell lines (Table 2.1 and Figure 2.1) indicating high purity 
of RNA. Based on the optimised protocol of RNA extraction, the used kit (GeneJET 
RNA purification kit) was able to extract and purify high-quality RNA from PBMCs. 
The optimised spinning time for the purification column was 75 seconds (Table 2.2), 
while optimum centrifuge rpm was selected as 14000 (Table 2.3). Combining the 
optimised parameters, both A260/280 and A260/230 ratios were >1.8 (Table 2.4 and Figure 
2.2) indicating that the method (Protocol D) is ideal. There was optimum RNA yield 
(3.71 ± 0.41 µg) with high concentration (74.28 ± 8.17 ng/µL), therefore, the final 
protocol (Protocol D) was selected (Figure 2.3). RIN of the PBMC-extracted RNA was 
>8.5 even after seven days (Table 2.5, Figures 2.4 and 2.5) which represents highly 
integrated RNA sample. 
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Table 2.1: RNA quality and quantity in human lymphoma cell 
lines with un-optimised protocol 
Cell lines* 
RNA purity RNA 
concentration 
(ng/μl) 
A260/280 A260/230 
Before DNase treatment 
RL-60 2.01 ± 0.05 2.05 ± 0.04 156.06 ± 0.12 
RL-75 2.04 ± 0.03 2.09 ± 0.04 476.05 ± 0.60 
HT-60 2.02 ± 0.04 2.01 ± 0.05 148.14 ± 0.55 
HT-75 2.01 ± 0.05 2.03 ± 0.03 405.06 ± 1.51 
After DNase treatment 
RL-60 1.98 ± 0.03 1.97 ± 0.03 155.98 ± 0.12 
RL-75 1.98 ± 0.02 1.98 ± 0.02  475.63 ± 0.60 
HT-60 1.95 ± 0.02 1.93 ± 0.01 147.75 ± 0.55 
HT-75 1.96 ± 0.04 1.95 ± 0.03 403.98 ± 1.51 
* Human promyelocytic leukaemia cell line derived from PBMCs. 
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Figure 2.1: RNA quality in human lymphoma cell lines 
RL-60, R-75, HT-60 and HT-75: Human promyelocytic leukaemia cell lines. 
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Table 2.2: Optimisation of the purification column spinning time 
Spinning time 
(seconds) 
RNA purity RNA 
concentration 
(ng/μl) 
Ideal 
condition A260/280 A260/230 
Before DNase treatment 
60 1.86 ± 0.03 1.82 ± 0.03 72.33 ± 5.86 ☓ 
75 1.95 ± 0.04 1.87 ± 0.03 104.33 ± 4.16 ✓ 
90 1.69 ± 0.04 1.75 ± 0.03 87.33 ± 6.03 ☓ 
After DNase treatment 
60 1.76 ± 0.02 1.74 ± 0.03 54.67 ± 3.51 ☓ 
75 1.89 ± 0.04 1.84 ± 0.02 78.67 ± 2.52 ✓ 
90 1.65 ± 0.02 1.70 ± 0.01 63.33 ± 1.53 ☓ 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
